A comparative study of demineralized freeze-dried bone allograft alone and with 1% metformin in the treatment of intrabony defects in patients with chronic periodontitis: A randomized clinical trial.

Autor:	Mitra DK; Department of Periodontology, TPCT's Terna Dental College and Hospital, Navi Mumbai, Maharashtra, India., Donde RJ; Department of Periodontology, TPCT's Terna Dental College and Hospital, Navi Mumbai, Maharashtra, India., Desai AB; Department of Periodontology, TPCT's Terna Dental College and Hospital, Navi Mumbai, Maharashtra, India., Ghangrekar KP; Department of Periodontology, TPCT's Terna Dental College and Hospital, Navi Mumbai, Maharashtra, India., Potdar PN; Department of Periodontology, TPCT's Terna Dental College and Hospital, Navi Mumbai, Maharashtra, India., Shetty GP; Department of Periodontology, TPCT's Terna Dental College and Hospital, Navi Mumbai, Maharashtra, India.
Jazyk:	angličtina
Zdroj:	Journal of Indian Society of Periodontology [J Indian Soc Periodontol] 2023 Jan-Feb; Vol. 27 (1), pp. 70-75. Date of Electronic Publication: 2023 Jan 03.
DOI:	10.4103/jisp.jisp_628_21
Abstrakt:	Background: Periodontal disease is ubiquitous and its treatment requires a detailed treatment plan. Biomaterials are often used along with demineralized freeze-dried bone allograft (DFDBA) for periodontal regeneration. One percent metformin has evolved as a regeneration material. This study was initiated to assess and compare the regenerative potential of DFDBA alone and with 1% metformin in the treatment of intrabony defects in subjects with chronic periodontitis. Materials and Methods: 20 sites with intrabony defects were diagnosed of which 10 were assigned to Group A (1% Metformin + DFDBA) and 10 to Group B (DFDBA alone). Clinical parameters were measured at baseline, 3, 6, and 9 months postoperatively, whereas radiographic parameters were measured at baseline and 9 months postoperatively, and data were statistically analyzed. Results: Both the groups showed a statistically significant improvement in probing pocket depth and relative attachment level at 9 months. Radiographically, a statistically significant reduction in defect depth was seen in both the groups at 9 months. There was no statistically significant difference between the two groups as far as crestal bone loss is concerned. No statistically significant difference was seen for clinical and radiographic parameters between the test and control groups. Conclusions: The addition of 1% metformin to DFDBA did not have any additional benefits in the treatment of subjects with defects which are intrabony. Competing Interests: There are no conflicts of interest. (Copyright: © 2023 Indian Society of Periodontology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu